Objectives: Several direct-acting agents against the hepatitis C virus (HCV) NS3 protease and NS5b polymerase have been developed in recent years to improve treatment of this viral infection. Of these, simeprevir is currently recommended for HCV genotype 1 and 4 infections, but genotypic assessment for the presence of 80K is required prior to simeprevir administration due to the reduced susceptibility of genotype 1 viruses carrying that polymorphism. Because the prevalence of 80K at baseline in genotype 1 viruses varies between reports, we wanted to assess its worldwide prevalence.
Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. The standard treatment used for many years was a combination of pegylated IFN and ribavirin. In 2011, two direct-acting antivirals (DAAs) against the HCV protease, telaprevir and boceprevir, were approved by the US FDA for use in HCV genotype 1-infected subjects. These drugs were added to the state-of-the-art therapy. Although this triple therapy has improved overall treatment efficacy compared with previous schemes against genotype 1 infection, it retains important side effects. In 2013, a novel PI, simeprevir, was approved for clinical use. It is directed against HCV genotypes 1 and 4, and selects for similar resistance profiles to those of boceprevir and telaprevir. Second-generation PIs are under clinical development, with broader genotype coverage and a higher genetic barrier to resistance. 1 HCV displays high genetic heterogeneity and genotypes vary greatly in sequence, contributing to the existence of natural polymorphisms that affect drug efficacy. Among the polymorphisms associated with resistance to simeprevir, the 80K and 80R variants in NS3 present significant fold changes in resistance compared with the WT 80Q (2.2-to 7.8-fold and 0.5-to 6.4-fold, respectively). 2 -4 Triple therapy with simeprevir showed 79% of sustained virological response (SVR) in therapy-experienced patients in a clinical trial, 5 with specific rates of 70% and 86% for subtypes 1a and 1b, respectively. However, subtype 1a-infected patients carrying the 80K polymorphism presented a 47% -75% SVR versus 78% -85% among those not carrying it. 6, 7 Both American and Despite the fact that 80K has been reported with particularly high prevalence in the USA, 10 recent reports have suggested that the prevalence of this mutation may vary among genotype 1 strains from distinct parts of the world. 11 -13 These reports, however, were of regional scope, and a full worldwide assessment has not been done. Moreover, surveillance on the prevalence of 80K in subtype 1b has been neglected due to earlier reports of very low prevalence in that subtype. The present study aims to survey the presence of the 80K and 80R polymorphisms in different countries and continents worldwide, highlighting the need to identify these polymorphisms before drug administration in specific populations, and allowing an evaluation of the actual efficacy of simeprevir-containing schemes at distinct geographical locations.
Methods
A total of 11 140 HCV genotype 1 NS3 protease sequences from naive patients in different continents and countries were obtained from the HCV Los Alamos and GenBank databases. After excluding sequences generated from single individuals (quasispecies clones) and those with missing data at codon 80 (incomplete NS3 sequences), 3082 sequences were retained for further analysis. Genotype 1 sequences had their subtypes (1a, 1b or others) determined by phylogenetic analysis with genotype/ subtype references (data not shown). South America contributed with sequences from a single country (Brazil), while Central America had no sequences available. 80K polymorphism frequency from Canada and Sweden was also additionally determined by compilation of available literature. 14, 15 Sequence alignment was performed with ClustalX v.2.0, 16 and the BioEdit platform v.7.0.5.3 17 was used for editing and analysis. 80K prevalence was directly extracted from the alignments based on geography (continent/country) and also stratified by genotype 1 subtypes.
Results
We have revisited HCV genotype 1 subtype classification for all sequences retrieved in public databases through phylogenetic analysis. Eleven sequences were found to be misclassified and had their subtype reassigned: six from France (five 1b to 1a, and one 1a to non-1a/non-1b), one from Germany (1a to 1b), one from Italy (1b to 1a), one from Switzerland (1a to 1b), one from Cyprus (1a to 1b) and one from Japan (1b to 1a). No sequences from North and South America, Oceania and Africa were misclassified. Moreover, we subtyped many sequences for which no subtype information was originally available (e.g. .100 sequences from Japan).
Approximately 30.4% (274/902) of the HCV NS3 protease sequences obtained from North America presented the 80K polymorphism, followed by 6.1% (61/996) of those from Europe, 4.7% (6/128) of those from Oceania and 3.7% (5/135) of those from Africa ( Table 1 ). The prevalence of 80K in Asia and South America was ,2% (1.3%, 9/699 and 0.4%, 1/225, respectively), despite the high number of sequences assessed. In North America, the USA and Canada presented the highest frequency of 80K: .40% in both countries (Table 1) . Switzerland showed a frequency of 14.7% (20/136) for this polymorphism, the highest in Europe, and France exhibited 6.8% (10/147). Despite the fact that some continents were not properly represented, interesting findings were observed. In some continents, such as Africa and Asia, a limited number of countries contributed sequences and/ or there were low numbers of sequences per country. An exception in Africa was Tunisia, with a significant number of sequences and an 80K prevalence of 3.1%. In Asia, Japan showed a large number of sequences, depicting a low prevalence of 80K (1.4%; Table 1 ). In South America, despite the fact that Brazil was the only country contributing sequences, a low prevalence of 80K was found (0.4%).
As expected, differences in the prevalence of 80K were observed between genotype 1 subtypes 1a and 1b. The former presented a higher prevalence of the polymorphism than the latter in most countries and continents (Table 1) , except for France; in this country a significant number of sequences was retrieved for both subtypes, which had similar rates of 80K prevalence (7.9% in 1a and 6.1% in 1b; Table 1 ). In Japan, the predominance of subtype 1b over 1a precluded any comparison between them, but a low prevalence of 80K was found. India presented only one genotype 1 sequence, represented by a non-1a/non-1b subtype.
We have also assessed the prevalence of the 80R polymorphism, described as reducing susceptibility to simeprevir, but it was very low or zero across the globe, except for Sweden, with a 3.8% prevalence (Table 1) .
Discussion
The DAA simeprevir is recommended for treatment of HCV infections caused by viral genotypes 1 and 4. The polymorphisms 80K and 80R in the viral NS3 protease impair the efficacy of this drug, and assessment of their occurrence is required prior to simeprevir prescription in resource-rich settings. However, disparate reports of 80K prevalence have been published in different areas of the world, and a universal assessment was therefore required.
In our HCV sequence assessment, Europe was the largest sequence contributor (n ¼ 996), followed by North America (n ¼ 902). Some continents were poorly represented, such as Africa, Asia and South America, with sequences obtained mostly from a single country. Nevertheless, disparate prevalence was found between the well-characterized developed countries and developing countries in South America and Asia, where large numbers of HCV-infected subjects are targeted for treatment with DAAs. Within Europe, subtype 1b was prevalent in Ireland, and no instances of 80K-harbouring viruses were found among 94 infections, making this country a putatively proper target for simeprevir-containing anti-HCV regimens. Conversely, a significant number of subtype 1b viruses carrying 80K was found in France (6.1%), contrary to the generalized idea that 80K prevalence in this subtype is negligible. The most important scenarios, however, were represented by developing countries. Brazil has an estimated 1.5 million people infected by HCV, 18 and will likely be one of the largest markets for anti-HCV drugs in the near future. Our analysis showed that ,1% of HCV subtype 1a viruses carried 80K (among 110 viral sequences analysed), and none of 115 subtype 1b sequences carried this mutation. HCV infection cases in HCV NS3 80K and simeprevir usage 2025 
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China were also noteworthy, and although a small number of sequences were available for analysis, no instance of 80K among genotype 1 sequences was observed.
Some studies suggested that Q80R does not confer reduced susceptibility of HCV to telaprevir and boceprevir. 2, 3, 14 Others have shown that this mutation confers 2.6-to 6.4-fold resistance to simeprevir, faldaprevir and asunaprevir, 4, 19 although the clinical significance of these findings is not yet known. The Q80R mutation was rarely observed in HCV genotype 1 sequences analysed in our study (0%-3.8%).
Overall, two important conclusions can be drawn from our data. Firstly, it is likely that in emerging countries such as Brazil and China, an assessment of 80K in HCV genotype 1 viruses is not required prior to simeprevir prescription. This would certainly represent an important economic issue for these countries, especially for Brazil, where a universal health system provides anti-HCV treatment free of charge to all in need, and where simeprevir is expected to be introduced into public healthcare in early 2015. Secondly, screening for 80K in HCV subtype 1b should be considered in specific developed countries, such as France and Japan, which show significantly higher frequencies of 80K in that subtype. Our observations raise an important issue about how the treatment of HCV infections should be managed worldwide, taking into account economic and technical aspects. 
